Previous Article | Next Article ![]()
Journal of Virology, March 2003, p. 3191-3203, Vol. 77, No. 5
0022-538X/03/$08.00+0 DOI: 10.1128/JVI.77.5.3191-3203.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.
Department of Medicine, Center for Molecular Medicine, Karolinska Institute, SE 171 76 Stockholm,1 Clinical Research Center, Karolinska Institutet, Huddinge University Hospital, SE 141 86 Huddinge, Sweden,2 Departments of Pediatrics and Microbiology, The University of Alabama at Birmingham, Birmingham, Alabama 3523323
Received 30 October 2002/ Accepted 26 November 2002
|
|
|---|
|
|
|---|
Most enveloped viruses, such as alpha-, orthomyxo-, paramyxo-, rhabdo-, and retroviruses, acquire their lipid envelope by budding at the plasma membrane (15). Upon this type of budding, mature virus particles are released directly into the extracellular space. In contrast, viruses that mature intracellularly bud into the lumen of intracellular compartments to acquire their final envelope (15, 56). Mature virus particles are then transported within the cell in membrane vacuoles, which upon fusion with the plasma membrane release virions extracellularly. For example, coronaviruses and poxviruses bud at the endoplasmic reticulum (ER)-Golgi intermediate compartment (ERGIC) (28, 51), Bunyaviridae and rubella virus bud at the Golgi complex (36), and HSV has been suggested to bud at the inner nuclear membrane (8, 31, 55) or into cytoplasmic vacuoles (29). In the case of budding at the inner nuclear membrane, subsequent maturation of the herpesvirus particle is believed to take place during passage of virus particles through the ER (56) or the Golgi complex (24). In contrast, more recent studies on HSV morphogenesis suggest that nucleocapsids undergo a sequential envelopment and de-envelopment crossing the nuclear membrane (5, 49), and thereafter the capsid will receive its final envelope by budding into subcellular vacuoles in the cytoplasm (50). A number of studies have presented evidence of different budding sites for HCMV. For example, structural electron microscopy (EM) studies have suggested that capsids receive their final envelope by budding into early endosomes (60), or into trans-Golgi cisternae containing viral glycoproteins (27, 47). Such vacuoles containing mature virions have been suggested to release infectious virus particles by excocytosis (27). Furthermore, studies using the fungal metabolite brefeldin A have demonstrated a cytoplasmic accumulation of naked virus particles in HSV-infected (6) and HCMV-infected (10) cells. This finding supports the hypothesis that the final envelopment occurs in the cytoplasm and implies an important role of the Golgi apparatus in this process. However, the site of the final envelopment for HCMV has not been clearly defined by methods examining the origin of the subcellular compartment for budding.
Since assembly processes are believed to be initiated by specific interactions between the nucleocapsid and a cytoplasmic extension of one or more of the viral glycoproteins (36, 48), the site of virus maturation can be examined by determining the accumulation of the viral glycoproteins in the budding compartment. To study the site of budding of HCMV particles, we performed EM and immunohistochemical analysis of HCMV-infected human embryonic lung fibroblasts (HF) at different time points after infection. Structural EM analysis suggested that tegumented virus particles bud into cytoplasmic vacuoles to acquire their final envelope. Colocalization studies of HCMV glycoprotein B (gB) and different markers for specific subcellular compartments were performed with HF, human umbilical vein endothelial cells (HUVEC), human pulmonary arterial endothelial cells (HPAEC), and arterial smooth muscle cells (ASMC) and revealed colocalization of gB with the Golgi resident enzyme mannosidase II, TGN (trans-Golgi network) 46, and the Rab 3 GTPase, which is a specific marker for secretory vacuoles. Immunogold labeling and EM analysis confirmed staining of the budding compartment and the viral envelope with HCMV gB, mannosidase II, and Rab 3 in HF. In contrast, lysosomal and endosomal markers were not detected on the virus-containing vacuoles. These results suggest that HCMV buds into Golgi-derived vacuoles, which are destined for the plasma membrane.
|
|
|---|
HPAEC medium was obtained from Clonetics, San Diego, Calif. The cells were maintained in EBM-2 (Clonetics) with growth factors according to the manufacturer's instructions at 37°C with 5% CO2. At 1 h prior to infection, the medium was changed to endothelial basal medium with 5% fetal calf serum, and the cells were cultured in this medium during the infection process. The cells were cultured in 0.2% gelatin-coated 175-cm2 tissue culture flasks (Falcon) or eight-well chamber slides (Nalge Nunc International) and used until passage 8 in the experiments.
HUVEC were cultured in EGM medium (Clonetics). At 1 h prior to infection, the medium was changed to endothelial basal medium with 5% fetal calf serum, and the cells were cultured in this medium during the infection process. The cells were cultured in 175-cm2 tissue culture flasks (Falcon) and eight-well chamber slides (Nalge Nunc International) and used until passage 8. The cells were infected at an MOI of 1 with an endothelium-adapted strain, TB40, kindly provided by G. Jahn and C. Sinzger, Department of Medical Virology, University of Tübingen, Tübingen, Germany.
Smooth muscle cells were isolated from aortic grafts obtained from patients undergoing surgery for aortic aneurysm with insertion of aortic grafts or from either aortic grafts or grafts of the iliaca vessels from transplantation donors. The cells were isolated by first removing the endothelial cells by cell scraping with a sharp instrument. The vessel was then divided into two different layers, the innermost layer (corresponding to the intima of the vessel) and the outermost layer (corresponding to the vessel media), by gentle separation of the two layers with a pair of tweezers. The aortic graft was cut into 1-mm pieces and cultured on cell culture dishes in SMGM 2 medium (Clonetics) with the addition of SMGM 2 SingleQuots (human epidermal growth factor [0.5 µg/ml], 0.5 ml; insulin [5 mg/ml], 0.5 ml; human fibroblast growth factor b [1 µg/ml], 1 ml; fetal bovine serum, 25 ml; GA-1000, 0.5 ml) for about 2 weeks, until smooth muscle cells had migrated from the explants. The cells were cultured in 175-cm2 cell culture flasks (Falcon). To determine the purity of the smooth muscle cell cultures, the cells were grown on chamber slides, fixed in 3% formaldehyde for 45 min at 4°C, and permeabilized with 0.3% Triton X-100 for 5 min. After fixation, the cells were stained for smooth muscle cell-specific fluorescein isothiocyanate (FITC)-conjugated antiactin (Sigma) and evaluated by fluorescence microscopy. The cells were fixed with methanol-acetone (1:1) at 4°C for 5 min, stained with FITC-conjugated anti-von Willebrand factor and endothelial cell-specific von Willebrand factor, and evaluated by fluorescence microscopy. Isotype controls for the antibodies were used in the experiments. The cultures were 100% positive for antiactin antibody and negative for von Willebrand factor.
Antibodies. For immunohistochemical analysis, antibodies specific for the markers Rab 1 to 6 (rabbit polyclonal immunoglobulin G), Rab 7, Lamp 1, and Lamp 2 (goat polyclonal immunoglobulin G), purchased from Santa Cruz Biotechnology, Santa Cruz, Calif., were used as 1:100 dilutions (1:10 dilutions in the immunogold experiments) from stocks of 200 µg/ml. TGN 46 (sheep anti-human antibody; Serotec, Oxford, United Kingdom) was detected with FITC-labeled rabbit anti-sheep antibody (Dako A/S, Glostrup, Denmark). Polyclonal mouse anti-human antibody directed against mannosidase II was kindly provided by Kelley Moreman and Marylin Farquhar, The University of Georgia, Athens. These antibodies were used in colocalization experiments with mouse or human anti-HCMV gB and detected with FITC- or rhodamine-phalloidin-conjugated swine, goat, or mouse F(ab)'2 fragments against rabbit, goat, or mouse Ig, respectively; FITC-conjugated rabbit anti-mouse immunoglobulin; FITC-conjugated goat F(ab)'2 anti-mouse antibody (Dako A/S); or phycoerythrin-conjugated goat F(ab)'2 fragments against human immunoglobulin (Southern Biotechnology Associates Inc., Birmingham, Ala.). Secondary antibodies were diluted in DAKO antibody diluent (DAKO A/S) and used as 1:100 dilutions. The following mouse monoclonal antibodies (MAbs), produced by William Britt, were used for CMV protein localization studies with immunofluorescence detection at 1:100 dilutions: UL99 (pp28), UL83 (pp65), UL82 (pp71), UL32 (pp150), UL55 (gB), UL75 (gH), and UL115 (gL) (44, 45).
Immunofluorescence staining of HCMV-infected cells. Monolayers of HF, HUVEC, HPAEC, or ASMC grown in 24- to 96-well tissue culture plates or on 8-well chamber slides (Nalge Nunc International) were infected with HCMV at an MOI of 1 and fixed at 1, 3, 5, 7, or 9 dpi. Uninfected and infected cells were washed in phosphate-buffered saline, fixed in either ice-cold methanol-acetone or 3% paraformaldehyde for 15 min at room temperature (RT), and permeabilized by 0.3% Triton X-100 treatment for 5 min. Samples were incubated with Serum-Free Protein Block (DAKO A/S) for 10 min at RT before being washed and stained with antibodies diluted in antibody diluent (DAKO A/S) or appropriate isotype controls. Both infected and uninfected cells were used in control experiments. Samples were mounted on glass slides by using fluorescent mounting medium containing 15 mM NaN3 (DAKO A/S). The secondary antibodies were made in the same species when two different antibodies were stained for colocalization experiments. For control purposes, the secondary antibody alone or cells treated with human, mouse, rabbit, or goat serum (DAKO A/S) (incubation in 1 to 3% serum for 15 min at RT) were stained for false fluorescence and autofluorescence (same control with both infected and noninfected cells). 4,6-Diamide-2-phenylindol (Sigma-Aldrich, St. Louis, Mo.) at 4 ng/ml was used to stain the nucleus blue.
Fluorescence microscopy and image analysis. Fluorescence microscopy analysis was performed with a DMRXA microscope (Leica Microsystems Gmbh, Wetzlar, Germany) equipped with a cooled charge-coupled device camera (model S/N 370 KL 0565; Cooke Corporation, Auburn Hills, Mich.). Filter sets for 4,6-diamide-2-phenylindol-Hoechst, FITC, Cy3, and Cy5 were obtained from Chroma Technology (Brattleboro, Vt.). The images were acquired and analyzed with the image processing software SlideBook 2.1.5 (Intelligent Imaging Innovations Inc., Denver, Colo.). Images were postprocessed and mounted in Photoshop 5.0 (Adobe Systems Inc., San Jose, Calif.) and printed on a Tektronix Phaser 860DP color printer (Xerox, Stamford, Conn.) or on a DS 8650 printer (Kodak, Rochester, N.Y.).
EM analysis. (i) Tissue preparation for structural EM analysis. To examine virus-infected cells (MOI of 1) by EM, uninfected and HCMV-infected cells were harvested at 1, 3, 5, 7, and 10 dpi and fixed in 2% glutaraldehyde in 0.1 M sodium cacodylate buffer-0.1 M sucrose with 3 mM CaCl2 (pH 7.4) at 4°C for 20 h. Fixed cells were collected by scraping with a wooden peg and pelleted in Eppendorf tubes. The pellets were washed in 0.15 M sodium cacodylate containing 3 mM CaCl2 (pH 7.4). Specimens were postfixed in 2% osmium tetroxide in 0.1 M cacodylate buffer containing 3 mM CaCl2 for 1 h at 4°C, dehydrated in ethanol followed by acetone, and embedded in LX-112. Sections were cut, placed on Formvar-coated copper grids, and stained with uranyl acetate followed by lead citrate. Sections were examined in a calibrated Philips 420 electron microscope at 80 kV.
(ii) Immunohistochemical gold labeling of HCMV-infected cells. Monolayers of uninfected and HCMV-infected HF were washed with phosphate-buffered saline and fixed in 3% paraformaldehyde-0.1% glutaraldehyde in 0.1 M phosphate buffer (PB) (pH 7.2) for 30 min at RT. Following fixation, cells were scraped with a wooden peg and pelleted in Eppendorf tubes. The pellet was infiltrated with 4% gelatin in 0.1 M phosphate buffer (pH 7.4) for 1 h, followed by fixation in the same fixative for 1 h at RT. The specimens were thereafter infiltrated with 2.3 M sucrose and frozen in liquid nitrogen. Sectioning was performed in an ultracryotome (Leica UCT) at -90°C by the method previously described by Tokuyasu (59). The sections were washed in 0.1 M PB, blocked with 10% normal goat serum for 10 min, and incubated with the MAbs at same dilutions as described above overnight at 4°C. Sections were rinsed in 0.1 M PB plus 0.1% normal goat serum. Bound antibodies were detected by secondary goat anti-mouse antibodies conjugated with 10-nm-diameter gold particles. After an additional washing step with 0.1 M PB, the specimen was fixed in 2% glutaraldehyde for 30 min and washed with distilled water four times for 1 min each, followed by final contrasting in 0.1 M uranyl acetate for 45 min.
(iii) Quantification of immunogold labeling. Gold beads are the number of gold particles (designated Au) counted on a selected micrograph or on a certain structure seen in the micrograph, such as the envelope membrane of the virion, dense bodies, or vacuoles. The area of the micrograph where gold staining was counted was measured in square micrometers. Background staining is given as Au per square micrometer. The quantification is based on the comparison between the parameters Au per square micrometer on virus particles, Au per square micrometer on dense bodies, and Au per square micrometer on virus-containing vacuoles in relation to the background staining. Several antibodies (e.g., Lamp 1, Lamp 2, Rab 4, and Rab 7) were not suitable or optimal for use in gold labeling analysis due to instability of the antibodies.
|
|
|---|
![]() View larger version (174K): [in a new window] |
FIG. 1. HCMV buds into cytoplasmic vacuoles. Structural EM was performed on HCMV-infected human lung fibroblasts at 5 dpi. An overview of the HCMV replication cycle at 5 dpi in an HCMV-infected HF is shown. (A) Virus particles undergoing envelopment in cytoplasmic vacuoles are indicated by arrows. PM, plasma membrane; NM, nuclear membrane. (B) Three morphologically different capsids, A, B, and C, are formed in the nucleus. (C and D) Tegumented capsids bud into cytoplasmic vacuoles (V) to acquire their envelope. (E) Mature virus particles (VP) and dense bodies (DB) exit the cell by fusion of the transporting vacuole and the plasma membrane to release its content to the extracellular space.
|
![]() View larger version (127K): [in a new window] |
FIG. 2. Immunofluorescent staining localizing HCMV protein expression in HCMV-infected HF at 5 dpi. The tegument proteins pp28 (B), pp71 (C), and pp150 (D) are found in the cytoplasm and in high concentrations around the nuclear membrane (pp28 in panel B) and in the Golgi region (pp150 in panel D). A possible cytoplasmic site of tegument protein acquisition is showed in the EM micrographs (A and J), where tegumented capsids accumulate around structures of dense stained material. The viral glycoproteins gL (F), gH (G), and gB (H) are expressed in the Golgi apparatus and in punctuate structures in the cytoplasm. Notable is the dot-like staining underneath the plasma membrane and in the cytoplasm close to the Golgi apparatus. Naked A, B, and C capsids that have traversed the nuclear membrane lose the acquired membrane when entering the cytoplasm (I). The different cell types HL 411 (E), HL 19 (K), HUVEC (L), and HPAEC (N) showed the same mechanism of envelopment by budding into cytoplasmic vacuoles. PM, plasma membrane; NM, nuclear membrane.
|
HCMV tegument proteins and glycoproteins localize to cytoplasmic compartments in close proximity to the Golgi apparatus. To localize the site of viral capsid tegument acquisition in the infected cells, MAbs reactive with the tegument proteins pp28, pp65, pp71, and pp150 were used to stain HCMV-infected HF, HUVEC, HPAEC, and ASMC. In these experiments, the viral tegument protein pp28 was present mainly in the nuclear membrane and in large vacuole compartments in the cytoplasm, which may correspond to the large sites of accumulation of electron-dense material (500 to 2,000 nm) that were observed in the cytoplasm by EM analysis (Fig. 2A). These round structures of large electron-dense material were generally surrounded by numerous tegumented capsids (Fig. 2A). While the pp71 protein was strongly localized to the nuclear membrane (Fig. 2C), the pp150 protein was present mainly in the cytoplasm, with a high concentration in the Golgi region as well as in punctuate structures in close association with the cell nucleus and the Golgi apparatus (Fig. 2D). While pp28, pp71, and pp150 were detected exclusively in the cytoplasm, pp65 was observed in the nucleus at 1 and 3 dpi and in both the nucleus and the cytoplasm at 5 and 7 dpi (Fig. 2 and data not shown). In contrast to the previously reported presence of the HCMV tegument proteins pp28, pp71, and pp150 in the nucleus (22), we did not observe either pp28, pp71, or pp150 in the nucleus at any time point examined between 1 and 9 dpi. Further confocal microscopy analyses of the cellular localization of the HCMV envelope glycoproteins gB, gH, and gL demonstrated a staining pattern similar to that of the tegument proteins pp71 and pp150 in the cytoplasm, with a high-intensity staining pattern around, and in, the Golgi region. In addition, the envelope glycoproteins gB, gH, and gL were present in small vacuoles around the Golgi apparatus and underneath the plasma membrane, which may correspond to the small (300- to 600-nm) virus-containing vacuoles observed by EM analysis (Fig. 1C, D, and E and 2E). Furthermore, while antibodies specific for gH and gL stained the nuclear membrane at early times in infection (Fig. 2F and G), gB was only rarely detected at the nuclear membrane (Fig. 2H). Thus, these results suggest that the tegumentation and envelopment appear to be separate processes.
Confocal microscopy analyses demonstrate colocalization of gB with Rab 3, TGN 46, and mannosidase II. To identify the site of intracellular accumulation of the major HCMV envelope glycoprotein gB by using specific intracellular markers, we performed colocalization experiments with antibodies directed against HCMV gB as well as markers for the following specific subcellular compartments: Rab 1 (ER and Golgi complex), Rab 2 (transitional ER and cis-Golgi network), Rab 3 (secretory vacuoles), Rab 4 (early endosomes) Rab 5 (early endosomes), Rab 6 (medial- and trans-Golgi cisternae), TGN 46 (trans-Golgi network), and mannosidase II (medial Golgi) (Table 1). The Golgi resident enzyme mannosidase II colocalized with HCMV gB in cytoplasmic vacuoles, in close association with the plasma membrane (HUVEC and HL 411 in Fig. 3) Furthermore, Rab 3 also demonstrated a strong colocalization with gB in cytoplasmic vacuoles (HL 411 and HPAEC in Fig. 3). In contrast, Rab 1, 2, 5, and 6 rarely colocalized with gB in the infected cells (HL 411 in Fig. 4). Similar results were obtained with HUVEC (data not shown). To further examine whether the site of accumulation of viral proteins coincided with a site where virus particles could be degraded, we performed colocalization experiments with antibodies directed against gB and the following markers: Rab 7 (late endosomes), Lamp I (late endosomes and lysosomes), and Lamp II (lysosomes). The HCMV gB-positive vacuole compartments were negative for all of these markers, which suggests that the cellular compartments containing enveloped virus particles do not enter a degradation pathway (data not shown). As expected, all markers tested showed a weak colocalization signal with gB in the Golgi region, most likely due to their common pathway of production. However, colocalization of gB and either Rab 1, Rab 2, Rab 4, Rab 5, Rab 6, Lamp I, or Lamp II was never observed in any distinct cytoplasmic compartment at any time point during infection (Fig. 4 and data not shown). Antibodies directed against Lamp 1 and Lamp 2 showed background staining in the immunofluorescence detection experiments.
|
View this table: [in a new window] |
TABLE 1. Antibody markers and their intracellular targetsa
|
![]() View larger version (67K): [in a new window] |
FIG. 3. Colocalization of gB (red) with the subcellular markers (green) mannosidase II (Man 2), Rab 3, Rab 4, and TGN 46 in HL 411. Colocalization was performed to identify the intracellular site of gB accumulation. Mannosidase II, Rab 3, and TGN 46 showed clear colocalizationwith gB in distinct vacuole compartments in the cytoplasm and in the Golgi region. The cytoplasmic, punctuate colocalization staining pattern of Rab 3, TGN 46, and mannosidase II is enlarged to show the distribution of cytoplasmic vacuoles (yellow dots). Rab 4 colocalized with gB to a lesser extent, but only in compartments next to the nuclear membrane or the Golgi stack. Uninfected cells stained with the same markers are shown in the left columns. The colocalization of Rab 3, mannosidase II, and TGN 46 with gB was confirmed in HPAEC, HUVEC, HL 19, and ASMC (bottom panels).
|
![]() View larger version (74K): [in a new window] |
FIG. 4. Colocalization of gB and the markers Rab 1, Rab 2, Rab 5, and Rab 6 in HCMV-infected HF cells at 5 dpi. Colocalization was performed to identify the intracellular site of gB accumulation. Rab 1, Rab 2, Rab 5, and Rab 6 did not show colocalization with gB. The four markers demonstrated a weak colocalization with gB in the Golgi apparatus but not in any intracellular compartment.
|
![]() View larger version (179K): [in a new window] |
FIG. 5. Immunogold localization of subcellular markers in HCMV-infected HF. Immunogold labeling was performed to identify the vacuole compartment detected by confocal microscopy. Secondary antibodies marked with colloidal gold were used to visualize the staining of gB (A), mannosidase II (B) Rab 3 (C), and Rab 5 (D). The HCMV gB, Rab 3, and mannosidase II antibodies stained the envelope membrane of virus particles (VP), dense bodies (DB), and the vacuole membrane (V).
|
|
View this table: [in a new window] |
TABLE 2. Statistical analysis of the immunogold labeling experimentsa
|
|
|
|---|
A number of investigations on herpesvirus assembly and egress have suggested two hypotheses for herpesvirus assembly (for reviews, see references 29 and 57). The earliest studies suggested that the final envelopment of the virion takes place at the inner nuclear membrane (7, 8). This hypothesis was expanded further to include modifications of the enveloped particle as it traversed and matured inside the ER-Golgi network compartments (9, 25). Thereafter, studies of the assembly process suggested that the envelopment of capsids occurred by passage though the inner leaflet of the nuclear membrane followed by a de-envelopment of capsids at the outer nuclear membrane. Finally, envelopment takes place by budding into cytoplasmic compartments (5, 41, 49). More recent models suggest that the final envelopment of the tegumented capsid occurs in the TGN by budding into vacuoles containing membranes with a high concentration of processed viral envelope glycoproteins (16, 18, 19, 32, 40, 65, 66). Our findings fit well with the latter hypothesis and extend the model to include a method for the virus to exit different infected cell types.
The tegument contains several proteins which form the characteristic proteinaceous material that surrounds the icosahedral herpesvirus capsids. Although the number of proteins and the size of the tegument seem to differ between the herpesviruses HSV (29), varicella-zoster virus (VZV) (54), and HCMV (17), the tegument proteins are expressed predominantly in the cytoplasm, where most of tegument acquisition likely takes place. Furthermore, EM analyses of the tegument acquisition for human herpesvirus 6 (HHV-6) suggest that this process takes place in close connection to the envelopment and de-envelopment processes when capsids are passing through the nuclear membrane in compartments termed tegusomes (41). Thereafter, the tegumented capsids have been implied to bud into cytoplasmic vacuoles to achieve their final envelope (41). In a number of studies examining HCMV tegument acquisition (43-45), the evidence suggests that virion tegument and envelope proteins accumulate in stable cytoplasmic compartments. These compartments express markers for the ERGIC, which is a dynamic compartment of the secretory pathway in close connection to both the ER and the Golgi apparatus. Here, we also localized the tegument proteins pp28, pp65, pp71, and pp150 to the ER and Golgi apparatus, in accordance with previous observations in HF, HUVEC, HPAEC, and ASMC. Since the tegument is located underneath the envelope in mature virus particles, the process of tegument acquisition has to take place earlier than the envelopment. We here observed an important difference between the accumulated expression of cytoplasmic tegument proteins and the cytoplasmic gathering of the viral glycoproteins in vacuoles around the Golgi apparatus and adjacent to the plasma membrane. Viral tegument proteins did not show punctuate staining closer to the plasma membrane but were limited to regions around the Golgi apparatus.
Our EM analyses showed that tegumented nucleocapsids were inserted into vacuole cavities by curving of the vacuole membrane, which then seems to wrap around the capsid in the budding process. The original concave face of the vacuole forms the viral envelope, and mature virions accumulate inside the vacuole compartment. These vacuoles were positive for gB, the Golgi marker mannosidase II, and Rab 3 and contained virus particles and dense bodies. Cytoplasmic vacuole compartments have previously been described for HHV-6 (41), VZV (26), and HCMV (50) but have not been characterized by staining for intracellular markers (39). Here, we observed an apparent increase in the number of vacuoles in HCMV-infected cells compared to uninfected cells by comparing the expression of intracellular markers in HCMV-infected compared to uninfected cells (data not shown). We further observed that the highly abundant large budding compartments for HCMV were not present in uninfected cells. Similar data that suggest that these vacuoles are virus induced have been reported for VZV (26). Interestingly, one study which examined the role of the PrV protein UL20 suggested an important role of this protein in the egress of vacuoles containing virus particles. Infection of Vero cells with a deletion mutant of PrV UL20 resulted in retention of enveloped virus particles in cytoplasmic vacuoles (13). Furthermore, infection of cells with a deletion mutant of the HSV type 1 UL20 gene results in an accumulation of virions in the perinuclear space, suggesting a role of this protein in nuclear egress (2). The HSV type 1 UL20 membrane protein has also been demonstrated to interfere with the exocytosis of virions and viral membrane glycoproteins at late times of infection (1). In addition, deletion of the PrV UL3.5 gene blocks the tegumentation and envelopment of cytoplasmic PrV capsids (14). However, it is presently unknown which proteins are responsible for the budding and egress of HCMV.
In contrast to our observations, a number of investigators have suggested that nuclear capsids bud through the inner nuclear membrane to acquire their final envelope. However, a final envelopment at the nuclear membrane is impossible in this case, since the capsid tegument acquisition must take place in the cytoplasm where most tegument proteins are accumulating. A consensus is now being developed that herpesviruses appears to exit the host cell by the pathway of envelopment, de-envelopment, and reenvelopment, based on studies mainly examining HSV and pseudorabies virus (29). Our data further substantiate this hypothesis, since we provide similar descriptive evidence for HCMV assembly. We suggest that the final viral envelope originates from the Golgi apparatus, as demonstrated by the detection of mannosidase II and TGN 46 on the budding compartment as well as on virus particles. The presumed involvement of the Golgi complex in HCMV morphogenesis is also supported by previous experiments using the fungal metabolite brefeldin A (10). Treatment of cells with this drug results in disintegration of the Golgi complex, and virus-infected cells treated with brefeldin A accumulate nonenveloped capsids in the cytoplasm. Our study presents the first evidence of the presence of Golgi-specific markers on intracellular virus-containing vacuoles. Similar to the case for HCMV, other members of the herpesvirus family, such as HHV-6 and VZV, as well as other viruses, including bunyaviruses and coronaviruses, have also been suggested to utilize Golgi-derived compartments for the final envelopment (reviewed in reference 26).
The prerequisite for budding to take place is the accumulation of glycoproteins in the budding compartment. A number of studies of intracellular trafficking of herpesvirus envelope glycoproteins have demonstrated the retrieval or endocytosis of viral glycoproteins from the plasma membrane into the budding compartment (4). HCMV gB is the major glycoprotein present on HCMV particles, and the protein is essential for production of new viral progeny. A previous study has found that the majority of infectious intracellular virus is contained within gB-coated vacuoles (11). Studies of the intracellular transport of gB initially proposed that endocytosis brings viral gB from the plasma membrane to a trans-Golgi vesicular compartment where they are used for envelopment (38). However, later studies examining the retrieval of HCMV gB in astrocytoma cells (12, 23), a mutant PrV gB (33), or PrV gE (58) have shown that endocytosis is not required for virion incorporation of these glycoproteins into the final envelope. Interestingly, not only viral proteins are present in the virus envelope. We and others have found that host cell-derived proteins such as CD13 (52), ß2-microglobulin (20), annexin II (64), a 45-kDa actin-related protein (3), and CD55 and CD59 (53) are present in the viral envelope. The reason why the virus incorporates host cell-derived proteins in the envelope is unknown, but evidence suggest a role of some of these proteins in the ability of the virus to avoid immune recognition (21).
Viral glycoproteins are processed through the Golgi network, where they are segregated into specific transport vacuoles and dispatched to their final destinations, i.e., the plasma membrane, secretory vacuoles, endosomes, or lysosomes (61). The secretory pathway of eukaryotic cells consists of a series of compartments that are interconnected by vesicular transport steps. At present, three groups of intracellular vacuole coats have been identified: membranes containing clathrin and plasma membrane-specific adaptation molecules that mediate endocytosis, membranes with TGN-specific adaptins that mediate transport from the TGN to late endosomes, and coatamer protein complex-containing coats found on Golgi-derived transport vacuoles (35). In this study, we identified the Golgi resident enzyme mannosidase II on the virus-containing vacuoles. Mannosidase II is present in the Golgi stack and processes mannoses on oligosaccharides to form a complex of oligosaccharides that are resistant to attacks by endoglycosidase H. TGN 46 is a trans-Golgi marker that has been indicated to play a pivotal role in directing HCMV glycoproteins in the secretory pathway (61). We further identified Rab 3 on the virus-containing vacuole, which suggest that the vacuole may enter a secretory pathway (37, 46). The Rab GTPases, which belong to a family of Ras-like enzymes, play key roles in the secretory pathway and membrane trafficking and have been used to identify specific vacuole membranes (34). Rab 3 is a marker for secretory vacuoles that are shuttled between the plasma membrane and the trans-Golgi compartment and would therefore be optimal for the virus to utilize for transport out of the infected cell. In support of this hypothesis, Rab 3D cycles between TGN 46-positive membranes and the plasma membrane (61). A study on HSV type 1 in rat dorsal root ganglion neurons identified the Golgi markers giantin, mannosidase II, and TGN 38 on cytoplasmic vacuoles, intracytoplasmic virions, and extracellular virions (30), further strengthening the hypothesis of a trans-Golgi origin of the cytoplasmic vacuoles utilized for HCMV envelopment.
In summary, our observations suggest the following model for HCMV assembly in fibroblasts, endothelial cells, and smooth muscle cells (Fig. 6). Naked nucleocapsids, formed in the nucleus, traverse the nuclear membrane and become tegumented through the exit pathway by an unknown sequential process. Viral glycoproteins accumulate in Rab 3-, TGN 46-, and mannosidase II-positive Golgi-derived vacuoles. The tegumented nucleocapsids become enveloped by budding into the gB-, Rab3-, TGN 46-, and mannosidase II-positive vacuoles to acquire their final envelope. The vacuoles are then transported to the plasma membrane in Rab 3-positive secretory vacuoles, and virus particles are subsequently released from the cells by fusion of the vacuoles with the plasma membrane. Further molecular studies have to be performed to reveal the molecular events that govern the budding process of tegumented HCMV capsids and identify the specific protein-protein interactions involved in the envelopment process.
![]() View larger version (128K): [in a new window] |
FIG. 6. Model of the HCMV envelopment and exit pathway. Naked nucleocapsids, formed in the nucleus, traverse the nuclear membrane and become tegumented through the exit pathway by an unknown process. Viral glycoproteins are released from the Golgi apparatus within small transport vacuoles. Fusion of these vacuoles results in the formation of large gB-, mannosidase II-, TGN 46-, and Rab 3-positive cytoplasmic vacuoles. The tegumented HCMV capsids become enveloped when budding into the vacuoles, acquiring the vacuole membrane as their envelope. The vacuoles are then transported to the plasma membrane, and virus particles are subsequently released upon fusion of the vacuoles with the cellular plasma membrane.
|
This work was supported by grants from the Swedish Medical Research Council (12615-01A, 00793-36B, and K2001-16X-12615-04A), the Tobias Foundation (1313/98 and 33/02), the Swedish Children's Cancer Foundation (1998/065 and 01/046), the Swedish Society of Medicine (1999-02-0347), the Heart and Lung Foundation (1999-41-305), and the Emil and Wera Cornells Foundation. C.S.-N. is a fellow of the Wenner-Gren Foundation, Sweden.
|
|
|---|
deenvelopment
reenvelopment pathway. J. Virol. 75:5697-5702.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»